Agios Pharmaceuticals (NASDAQ:AGIO) reported Q2 2018 earnings this Morning, coming in at ($1.19) per share, beating Wall Street’s estimates of ($1.67) per Share. Revenue for the quarter came in at $40.40 million beating analyst estimates of $12.47 million Recent Insider Trading for Agios Pharmaceuticals (NASDAQ:AGIO)
- On 7/25/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $84.58 per share and the total transaction amounting to $173,389.00.
- On 7/9/2018 Carman Alenson, Insider, sold 272 with an average share price of $84.94 per share and the total transaction amounting to $23,103.68.
- On 7/5/2018 Scott Biller, Insider, sold 3,000 with an average share price of $83.50 per share and the total transaction amounting to $250,500.00.
- On 6/22/2018 Steven L Hoerter, Insider, sold 2,050 with an average share price of $97.58 per share and the total transaction amounting to $200,039.00.
- On 6/14/2018 Kaye I Foster-Cheek, Director, sold 9,000 with an average share price of $93.55 per share and the total transaction amounting to $841,950.00.
- On 6/12/2018 Christopher Bowden, Insider, sold 2,000 with an average share price of $92.89 per share and the total transaction amounting to $185,780.00.
About Company Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML. The company also develops Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase I clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase I clinical trial for advanced solid tumors; Phase III clinical trials for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination and Phase III clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase I clinical trial for the treatment of hematologic malignancies; and AG-348, a small molecule potent activator that is in Phase II clinical trials for the treatment of pyruvate kinase deficiency. Agios Pharmaceuticals has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is based in Cambridge, Massachusetts.Recent Analyst Rating for Agios Pharmaceuticals (NASDAQ:AGIO)
Recent Trading for Agios Pharmaceuticals (NASDAQ:AGIO) Shares of Agios Pharmaceuticals closed the previous trading session at with 660300 shares trading hands.